Feedback Plc (LON: FDBK) have updated shareholders about a new trial with Pennine Acute Hospitals NHS for its new medical communication platform, Bleepa.

Shares of Feedback plc (LON: FDBK) are trading at 1p. 18/11/19 14:34BST.

Bleepa is a platform which enables clinicians to access medical grade images through smartphones, tablets and desktop computers.

Shareholders can be optimistic, as it seems that the NHS have bought into the Bleepa software after agreeing a trial deal.

Feedback added that the trial is set to go live in December, and last for approximately three months to allow a full review of the system.

Seniority at Feedback anticipated that the pilot will be extended to include other clinical teams within the Trust, and expects diversification into the Orthopaedic and Vascular sector.

Dr Tom Oakley, CEO of Feedback, commented:

“Pennine Acute Hospitals NHS Trust is a renowned adopter of new technology given its status as a GDE Fast follower site, and we look forward to working with the team on our first pilot study of Bleepa^®. We believe that Bleepa will accelerate the process of requesting a specialist opinion from colleagues, ultimately resulting in better care for patients, faster.

“The Pennine Acute Hospitals NHS Trust pilot study is our first, but with the interest we have received since the launch of Bleepa at the NHS Expo 2019 in September, we anticipate more to follow.”

Libby Woodcock, EPR Transformation Manager of Pennine Acute Hospitals NHS Trust, commented:

“Transforming clinical services by providing digital enablement is always high on our agenda and we are excited to be involved.”

Dr Georges Ng Man Kwong, Consultant Chest Physician and CCIO of Pennine Acute Hospitals NHS Trust, commented:

“Bleepa is addressing a direct clinical challenge to better support our busy respiratory clinicians (at the Royal Oldham Hospital) by improving referral process and patient care. Each referral requires rapid and reliable access to radiology images and clinical handover information, and a means of messaging referring teams and documenting outcome. Bleepa has the potential to bring this together for our clinicians and therefore for our patients. We are delighted to be involved with this innovation solution.”

Feedback have also said the strategic review for its TexRAD medical image analysis technology has needed further developments to support a US Food & Drug Administration submission.

“We have made some product modifications to TexRAD Research in response to customer feedback and are evaluating the impact of these on revenue. In the near term, we will continue to sell TexRAD within the research setting through third party distributors which provides a more cost-effective avenue for maintaining our sales efforts. As a result, we have reduced the resources associated with TexRAD,” said Oakley.

Bezeq Tel (TLV: BEZQ) have seen their shares dip following a modest trading update released to shareholders on Monday.

Shares in the Israeli telecoms firm dipped 0.28% on Monday to ILS286. 18/11/19 14:10BST.

The firm reported a larger than expected fall in third quarter profit, and informed shareholders that it expected a large 2019 loss.

Bezeq Tel alluded to two major write downs of its business units as one of the main reasons for the loss expected in financial 19. Israel’s largest telecom provider is currently undergoing a change of ownership which has led to operational and structural changes.

The firm reported a profit of ILS191 million, down from the 2018 figure of ILS234 million, additionally this was short of analyst expectations of ILS198 million.

As well as the write downs of its business units, Bezeq reported the higher financing expenses contributing to the poor update.

Revenue fell 2.3% to ILS2.25 billion, which did beat analyst expectations of ILS2.23 billion.

The company maintained its forecast for 2019, expecting a net loss of ILS1.1 billion.

Bezeq is in the midst of a major restructuring with several parallel early retirement plans and cost-cutting measures,” Barclays (LON: BARC) analyst Tavy Rosner said. “These are starting to pay off, as demonstrated by the 4% decrease in salaries.”

“We hope that the new policy that will be formulated will enable us to launch fibre optic services for the private sector in Israel on an economic basis,” CEO David Mizrahi said in a statement.

Volkswagen (ETR: VOW3) have seen their shares dip after a statement was issued on Monday identifying a gloomy annual outlook.

Shares of Volkswagen dipped 3.95% to €175 on Monday. 18/11/19 13:46BST.

At the end of October, it was reported that Volkswagen’s sales revenue and profit grew between January and September.

Despite the positivity, seniority do not seem so confident on the full year guidance for the german automobile firm.

Volkswagen highlighted that in 2020 operating profit will remain between 6.5 and 7.5%.

We are continuing to pursue our ambitious strategic financial targets for 2020 and 2025,” Frank Witter, the member of the Volkswagen Group Board of Management responsible for Finance and IT.

Frank Witter said: “The Volkswagen Group remains very robust in the face of increasingly difficult economic conditions. However, we will have to apply systematic cost discipline to reach our long-term goals.” Witter concluded “We also confirm our outlook for 2019,”.

Volkswagen join Nissan (TYO: 7201) in a list of firms who have been pessimistic on their guidance for 2019 amid tough market conditions.

In a time where the global automobile market has experienced a slowdown, it seems that seniority at Volkswagen are feeling the slump.

Volkswagen have indeed given better updates compared to rivals, where the German firm have seen both profit and revenue gains.

Global rival such as Suzuki (TYO: 7269) have not been so lucky, seeing major slumps in Indian business. Whilst firms have attempted to combat slow business through mergers, as seen with Fiat Chrysler (NYSE: FCAU) and Peugeot (EPA: UG).

H&T Group Plc (LON: HAT) have seen their shares sink after the FCA triggered an investigation into ‘certain aspects and files’.

The FCA pledged to look into the companies high-cost short term credit (HCSTC) and unsecured loans business.

The review is focussing on H&T’s creditworthiness assessments and lending processes for HCSTC loans in light of new rule changes over affordability assessments, it said today.

Shares of H&T have sunk 16.99% during Monday trading to 307p. 18/11/19 13:27BST.

H&T confirmed to shareholders that it has temporarily ceased all HCSTC operations due to the ongoing investigation.

For financial 2019, H&T expected revenues from HCSTC unsecured lending to total less than 4% of total group revenue.

The FCA review is focusing on H&T’s creditworthiness assessments and lending processes for HCSTC loans, in light of regulatory changes.

H&T said it is cooperating with FCA and the review will result in changes to its policies and procedures relating to the provision of unsecured HCSTC loans.

H&T have said that they will also review historical lending practices to look into any issuances of customer redress.If redress applies, then the firm will fund it from existing financial resources.

In spite of the FCA review, H&T said that it continues “to trade well and in line with the dynamics set out in its statement of 30 September 2019.”

IQE PLC (LON: IQE) have seen their shares plummet across Monday trading after the firm announced expectation for a financial 2019 loss.

The British semiconductor company lowered its annual revenue forecast and warned shareholders that it will report a mid single digit operating loss for 2019.

As a result, shares plummeted 19.85% to 52p. 18/11/19 12:47BST.

The British firm expects revenue to be between £136 million and £142 million for 2019, where previous guidance was issued in the range of £140 million and £160 million.

In 2018, the company generated revenue of £156.3 million and adjusted operating profit of £16 million

The company highlighted good growth in its Photonics division, but this will do little to appease shareholders in what seems a very poor year of trading for the Cardiff based technology firm.

IQE further said that it has taken steps to reduce costs and 2019 capital expenditure is expected to be at the lower of the £30 million to £40 million guidance range and net debt to be between £15 million to £20 million.

“IQE has experienced very challenging market conditions in 2019. Shortfalls in revenue relate predominantly to two major customers, with whom IQE is confident it has not lost share and who remain very well positioned for returns to growth in 2020. Indeed, the company remains well positioned to capitalise on an expanding future compound semiconductor market opportunity driven by the macro trends of 5G and connected devices,” said IQE Chief Executive Drew Nelson.

Shares of Jangada Mines have rallied after the firm reported a new discovery at its Pitombeiras project in Brazil.

Shares of Jangada rallied 12.97% to 2p on Monday. 18/11/19 12:09BST.

Jangada said it identified eight magnetic anomaly targets to follow further exploration operations at Pitombeiras, located in Brazil.

The AIM listed (INDEXFTSE: AXX) natural resources company started a new exploration operation in Pitombeiras back in October.

The firm reported that high grade vanadium, titanium and iron was found at the surface which sparked shareholder optimism.

This will see pre-drilling exploration concluded by the end of the final quarter of 2019 and a three-month drilling programme to commence in January 2020.

An extensive fully funded programme is planned to provide the necessary technical information, Jangada said, which is expected to be available in the second quarter of 2020.

Janganda said the program includes the completion of up to 2,500 meters of diamond drilling.

Brian McMaster, Chairman of Jangada, said: “We continue to be highly encouraged with the results from the ongoing exploration programme at Pitombeiras. Our recent work has discovered a new target we call Goela, which adds substantial footprint to the overall prospect beyond the previously announced JORC Exploration Target. Excitingly, it is possible that Pitombeiras and Goela are linked and form one large deposit. Our January 2020 drilling campaign will look at the possible connection between these two mineralised bodies. In total, we have identified eight magnetic anomaly targets to follow up with further exploration work. Additionally, our exploration license was extended for an additional three years by the Brazilian mineral authority. Jangada is entering a truly exciting phase.”

Shares of Consort Medical PLC (LON: CSRT) have rocketed on Monday after it was reported that a takeover deal had been finalized.

Shares of Consort rocketed 43.25% to 1,040p. 18/11/19 11:29GMT.

Sweden based Recipharm AB (STO: RECI-B) have acquired Consort for a £505 million deal which has spiked shareholder appetite.

The full terms of the deal are yet to be disclosed, however a unit of Recipharm will pay 1,010 pence in cash for each share of Consort.

Christopher Brinsmead, chair of Consort, said: “We believe that Recipharm’s businesses are highly complementary to our own and the board intends to unanimously recommend the offer from Recipharm which represents a 39% premium to our share price.”

The enlarged Recipharm group is set to become a top five global CDMO, and this will allow Recipharm to offer integrated device development.

The offer is set to be fully financed through bank facilities, to be partly repaid by proceeds from a proposed share issue.

Additionally, Consort reported annual pro forma revenue of £292 million (SEK 3,633 million) and pro forma EBITDA of £47 million (SEK 587 million).

Thomas Eldered, Chief Executive Officer of Recipharm, said: “I am excited at the prospect of combining Recipharm with Consort, which is extremely complementary. In our view, Bespak is already acknowledged as a leading drug device developer and manufacturer and is a perfect fit for Recipharm’s broader pharmaceutical capabilities. The enlarged group will be able to provide finished dose forms in Bespak’s key technologies and provide customers with a far more integrated approach. The Aesica business will further expand our capabilities and capacities in both API and finished dose manufacturing whilst providing access to a new customer base”.

Jonathan Glenn, Chief Executive Officer, of Consort added: “Consort’s strategy has been to focus on expanding its businesses into new markets and geographic territories, and on developing our combined drug/device offering. Recipharm’s capabilities and footprint in drug manufacturing will enhance both our Bespak and Aesica businesses. We believe that customers of both businesses will value the offering and enhanced scale of the combined business”.